Stock Analysis

Northrop Grumman (NYSE:NOC) Advances Rocket Motor Tests With Raytheon For U.S. Army's NGSRI

NYSE:NOC
Source: Shutterstock

Northrop Grumman (NYSE:NOC) recently completed four successful tests of its flight-ready Highly Loaded Grain solid rocket motors in collaboration with Raytheon. This milestone, achieved in under six months, demonstrates the company's innovative capabilities, supporting the performance of its Next-Generation Short-Range Interceptor for the U.S. Army. The company's share price increased by 3% over the last quarter, amid a steady 1% market gain and broader industry optimism driven by developments in tariff negotiations and economic data. Northrop Grumman's quarterly dividend declaration and ongoing share buyback programs likely added confidence to investors during this period.

Every company has risks, and we've spotted 2 warning signs for Northrop Grumman you should know about.

NYSE:NOC Earnings Per Share Growth as at Jun 2025
NYSE:NOC Earnings Per Share Growth as at Jun 2025

AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

The recent successful tests of Northrop Grumman's Highly Loaded Grain solid rocket motors underscore the company's innovative capabilities and could bolster its revenue and earnings forecasts. The collaboration with Raytheon on the Next-Generation Short-Range Interceptor, coupled with strong industry optimism, suggests potential for enhanced performance over the coming years. These developments may lead to increased contract awards, particularly with the expected boost from the U.S. defense budget, potentially supporting future revenue growth.

Over the past five years, Northrop Grumman's total shareholder return, including both share price appreciation and dividends, was 56.46%. This reflects the company's capacity to generate long-term investor returns. In contrast, over the last year, the company's performance matched the US market's 11.6% return, but it underperformed relative to the US Aerospace & Defense industry's 32.4% return.

The share price's recent 3% rise aligns with market optimism and is a step toward closing the gap to the consensus price target of US$542.32. Currently trading at a 10.1% discount to this target, the anticipated revenue boost from Northrop Grumman's record backlog and recent technological advancements could help drive investor confidence further. As revenue is forecasted to grow 4.7% annually, compared to industry averages, meeting these price targets will depend on the company's ability to manage rising costs and maintain margin stability.

Take a closer look at Northrop Grumman's potential here in our financial health report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Northrop Grumman might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com